Kadans Science Partner welcomes Myricx Bio to London Innovation Centre

Myricx Bio joins Kadans’ pioneering innovation centre in Canary Wharf, providing the facilities for its future expansion and pipeline progression, following a recent £90m Series A financing

Kadans Science Partner (Kadans) is pleased to welcome Myricx Bio (Myricx) to its London Innovation Centre at 20 Water Street, Canary Wharf.

Myricx, an innovative UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs) for the treatment of cancer, will move its headquarters to the London Innovation Centre, taking a mix of laboratory and office space.

Myricx joins a great collective of other life sciences companies based at Kadans Science Partners’ London Innovation Centre which sits within the wider Canary Wharf life sciences ecosystem. The state-of-the-art facility comprises 40,000 sq. ft of fully fitted, flexible, CL2 wet labs and offices, ranging from bespoke 250 sq. ft to over 2,000 sq. ft labs, with tenants having the option of renting a bench in the CoWorking lab, or taking their own private lab.

Following Myricx’s recent £90m ($114m) Series A financing, the Company is building out its proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform as well as advancing its pipeline of NMTi-ADCs through clinical proof of concept, targeting clinically validated tumour-associated antigens. Myricx was spun out of Imperial College London and the Francis Crick Institute in 2019.

Myricx Bio COO, Julie Mead commented: “We are excited to take this next step and join Kadans’ London Innovation Centre as we grow our in-house R&D capabilities and management team, following the recent close of our £90m Series A financing. When looking to expand our footprint, it was important to us that we located a supportive, well-connected and dynamic environment in London, where we were founded, especially as we prepare to become a clinical stage company. We have found that environment in the Canary Wharf ecosystem, where the London Innovation Centre offers us excellent lab and office facilities, as well as a wider biotech network, which together will support our next phase of growth.”

Katie Nelson, Head of Leasing UK & Ireland, Kadans Science Partner, said: “We are really pleased that Myricx has chosen the London Innovation Centre to establish its headquarters, joining the growing community of life sciences companies at the facility and across the Canary Wharf estate. Kadans Science Partner ethos is to support our tenants with the full life cycle of their journey through its connected ecosystem which we can do across our London, UK and European Portfolio. It is encouraging to further expand our community at the London Innovation Centre, where we are seeing continued demand for flexible, high quality, affordable lab facilities in London. Myricx is an example of an innovative, growing business recognising the benefits of being situated in Canary Wharf’s growing science, health and technology district, with a community committed to collaboration and innovation.”

The London Innovation Centre provides flexible, fully serviced CL2 wet-lab laboratory and innovative workspaces for early-stage life science, biology and pharma organisations. Myricx joins a host of life sciences and healthcare organisations already based at the London Innovation Centre as well as wider Canary Wharf tenants, including AviadoBio at 20 Water Street and hVIVO, Genomics England, Barts Health NHS Trust, Medicines and Healthcare products Regulatory Agency, Medical Defence Union, General Pharmaceutical Council and NHS Transformation across the estate.

Continuing to build upon the Canary Wharf Life Science Ecosystem, Kadans and Canary Wharf Group are progressing their pioneering partnership to develop the tallest and most technically sophisticated purpose-built commercial laboratory building in the world. One North Quay is set to be an 823,000 sq ft GIA commercial vertical health and life sciences campus, on the 3.3-hectare North Quay site, which is expected to be complete in 2027.

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-Myristoyltransferases (NMT) for the treatment of cancer.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets that are key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour-associated antigens and cancer cell types.

Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Abingworth, Brandon Capital Partners, British Patient Capital Cancer Research Horizons, Eli Lilly and Company, Novo Holdings, Sofinnova Partners.

For further information please contact

At the Company
Dr Robin Carr, CEO, Myricx Bio
info@myricxbio.com

Media Enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 72658